Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.

Marzia Palma Lotta Hansson Tom A MulderLars AdamsonBarbro Näsman-GlaserIngrid ErikssonKia HeimerssonHarriet RyblomFariba MozaffariAnn SvenssonGiusy GentilcoreAnders Österborg Håkan Mellstedt

Published in: European journal of haematology (2018)

Lenalidomide alone or in combination with GM-CSF and low-dose CTX as immune adjuvant to the Apo-DC vaccine elicited tumor-specific T-cell responses in CLL patients. However, unexpected toxicity was observed and caution is suggested in further exploring this drug as immune adjuvant in CLL.

Keyphrases

chronic lymphocytic leukemia
newly diagnosed
end stage renal disease
low dose
early stage
dendritic cells
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
high dose
stem cell transplantation
patient reported
multidrug resistant
drug induced
adverse drug